1-3 of 3
nausea
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2a study of 177 Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Arne Kolstad, Tim Illidge, Nils Bolstad, Signe Spetalen, Ulf Madsbu, Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Noelle O'Rourke, Matthew Beasley, Wojciech Jurczak, Unn-Merete Fagerli, Michal Kaščák, Mike Bayne, Aleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4091–4101.
https://doi.org/10.1182/bloodadvances.2020002583
Published: 2020
Includes: Supplemental data
Journal Articles

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Clinical Trials & Observations
Je-Hwan Lee, Stefan Faderl, John M. Pagel, Chul Won Jung, Sung-Soo Yoon, Animesh D. Pardanani, Pamela S. Becker, Howard Lee, Jeongeun Choi, Kyoungjune Lee, Minkyoung Kim, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2020) 4 (9): 2032–2043.
https://doi.org/10.1182/bloodadvances.2019000757
Published: 2020
Includes: Supplemental data
Journal Articles

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Clinical Trials & Observations
Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1939–1949.
https://doi.org/10.1182/bloodadvances.2019030916
Published: 2019